Ghassan K. Abou-Alfa, MD, Highlights Approval of Tremelimumab and Durvalumab in Unresectable HCC

Video

Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.

In an interview with CancerNetwork®, Ghassan K. Abou-Alfa, MD, an attending physician at Memorial Sloan Kettering Cancer Center, spoke about the FDA approval of tremelimumab (Imjudo) in combination with durvalumab (Imfinzi) for the treatment of patients with unresectable hepatocellular carcinoma.1

Abou-Alfa highlighted key findings from the phase 3 HIMALAYA study (NCT03298451) that led to the FDA approval, which showed 31% of patients receiving tremelimumab and durvalumab had an improved 3-year survival period compared with 20% of those who were treated with sorafenib (Nexavar).2 Although more research is necessary to improve the treatment of patients with unresectable hepatocellular carcinoma, he indicated that the newly-approved Single Tremelimumab Regular Interval Durvalumab (STRIDE) regimen is a step in the right direction in the management of this disease.

Transcript:

[Hepatocellular] carcinoma is still not a curable disease. As such, it's definitely a cancer with an unmet need, because we did not cure people [only provided an option for treatment]. If anything, the advent of the durvalumab plus tremelimumab [regimen] that we now call the STRIDE regimen based on the HIMALAYA study, is no doubt a step in the right direction for further improvement and survival. However, a response [displayed] can be a complete response and will be [shown] in survival that are matching up to 1/3 of the patients having a 3-year overall survival. This is no doubt a step in the right direction, but by all means, there’s still more work to do.

References

  1. Imjudo (tremelimumab) in combination with Imfinzi approved in the US for patients with unresectable liver cancer. News Release. AstraZeneca. October 24, 2022. Accessed October 31, 2022. https://bit.ly/3Fbwx1w
  2. Abou-Alfa GK, Chan SL, Kudo M, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab and durvalumab as first-line therapy in patients with unresectable hepatocellular carcinoma: HIMALAYA. J Clin Oncol. 2022;40(suppl 4):379. doi:10.1200/JCO.2022.40.4_suppl.379
Recent Videos
Skin toxicities are common with targeted therapies for GI malignancies but can be remedied by preventative measures and a collaboration with dermatology.
Although 1 of 21 patients with liver-dominant NETs died due to RILD in the phase 1 study, no RILD-induced deaths were observed in the phase 2 trial.
A simulation procedure helped to ascertain chemotherapy tolerability before administering radioembolization therapy for NETs with liver metastases.
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
212Pb-DOTAMTATE showed “unexpectedly good” outcomes among those with gastroenteropancreatic neuroendocrine tumors, said Mary Maluccio, MD, MPH, FACS.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
Better defining which patients with GI cancers are preferred candidates for adoptive cellular therapies may help optimize outcomes.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
Related Content
Receiving treatment at an academic center may improve the probability of receiving subsequent curative care among those with hepatocellular carcinoma.

Post-IO Curative Treatment Conversion May Prolong Survival in Liver Cancer

Russ Conroy
November 14th 2025
Article

Receiving treatment at an academic center may improve the probability of receiving subsequent curative care among those with hepatocellular carcinoma.

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap

Nicholas James Hornstein, MD, PhD;Timothy Brown, MD;Udhayvir S. Grewal, MD
November 3rd 2025
Podcast

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

Neoadjuvant Cemiplimab/SBRT Yields Improved DFS in Resectable HCC

Neoadjuvant Cemiplimab/SBRT Yields Improved DFS in Resectable HCC

Ariana Pelosci
November 12th 2025
Article

DFS rates at 2 years were improved with cemiplimab plus SBRT vs cemiplimab alone in patients with resectable hepatocellular carcinoma.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Bezuclastinib/Sunitinib Improves Efficacy Vs Sunitinib Alone in GIST

Bezuclastinib/Sunitinib Improves Efficacy Vs Sunitinib Alone in GIST

Ariana Pelosci
November 11th 2025
Article

Results from the PEAK trial showed increased PFS in the bezuclastinib plus sunitinib arm vs sunitinib alone for patients with GIST.

Data from the phase 2 INTERACT-ION trial support further investigation of the potential synergistic effect of ezabenlimab plus adaptive chemoradiotherapy.

Ezabenlimab Combo Yields Activity in Advanced Squamous Cell Anal Carcinoma

Russ Conroy
November 8th 2025
Article

Data from the phase 2 INTERACT-ION trial support further investigation of the potential synergistic effect of ezabenlimab plus adaptive chemoradiotherapy.